Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Get Free Report) shares gapped down prior to trading on Friday. The stock had previously closed at $151.02, but opened at $129.00. Belite Bio shares last traded at $128.7930, with a volume of 194,973 shares traded.
Belite Bio News Roundup
These are some of the BLTE news items that stood out recently:
- Neutral Sentiment: HC Wainwright retained its Buy rating and $245 price target, while making small cuts to its 2027 earnings estimates. MarketBeat analyst estimates
- Negative Sentiment: The FDA extended its review of Belite Bio’s tinlarebant NDA by three months, setting a new action date of May 12, 2027. The agency needs additional time to review submitted information; it expects to communicate proposed labeling and any potential postmarketing requirements by April 12 if no major deficiencies emerge. The longer wait for a decision weighed on shares. Belite Bio FDA timeline announcement
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on BLTE. Canaccord Genuity Group increased their price objective on shares of Belite Bio from $303.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, November 16th. Morgan Stanley increased their price objective on Belite Bio from $201.00 to $206.00 and gave the company an “overweight” rating in a report on Friday, August 14th. UBS Group reiterated a “buy” rating on shares of Belite Bio in a report on Thursday, September 3rd. Cantor Fitzgerald lifted their target price on shares of Belite Bio from $266.00 to $270.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Finally, Mizuho lifted their target price on shares of Belite Bio from $221.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, November 16th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Belite Bio presently has an average rating of “Moderate Buy” and a consensus target price of $226.91.
Belite Bio Trading Down 15.7%
The stock has a 50-day moving average price of $157.61 and a 200 day moving average price of $159.69. The stock has a market capitalization of $5.13 billion, a price-to-earnings ratio of -46.66 and a beta of -1.19.
Belite Bio (NASDAQ:BLTE – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.19. Equities research analysts anticipate that Belite Bio, Inc. Sponsored ADR will post -3.06 earnings per share for the current year.
Insiders Place Their Bets
In other news, CFO Hao-Yuan Chuang sold 49,433 shares of the business’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $187.64, for a total transaction of $9,275,608.12. Following the completion of the sale, the chief financial officer owned 44,000 shares in the company, valued at $8,256,160. The trade was a 52.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Hendrik Scholl sold 2,000 shares of Belite Bio stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $165.99, for a total transaction of $331,980.00. Following the transaction, the insider directly owned 12,500 shares in the company, valued at approximately $2,074,875. This represents a 13.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 170,330 shares of company stock valued at $32,301,098. 13.29% of the stock is currently owned by corporate insiders.
Institutional Trading of Belite Bio
A number of hedge funds have recently made changes to their positions in the business. Affinity Asset Advisors LLC grew its holdings in Belite Bio by 225.0% in the 1st quarter. Affinity Asset Advisors LLC now owns 65,000 shares of the company’s stock valued at $10,364,000 after buying an additional 45,000 shares in the last quarter. Candriam S.C.A. bought a new stake in shares of Belite Bio in the third quarter valued at about $10,711,000. The Manufacturers Life Insurance Company bought a new stake in shares of Belite Bio in the first quarter valued at about $3,125,000. Renaissance Technologies LLC acquired a new position in shares of Belite Bio in the first quarter valued at about $8,291,000. Finally, Alberta Investment Management Corp acquired a new position in shares of Belite Bio in the third quarter valued at about $4,076,000. 0.53% of the stock is owned by institutional investors and hedge funds.
About Belite Bio
Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.
Featured Stories
- Five stocks we like better than Belite Bio
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.
